Raymond James Financial Inc. Invests $1.95 Million in uniQure (NASDAQ:QURE)

Raymond James Financial Inc. bought a new stake in uniQure (NASDAQ:QURE) during the fourth quarter, according to its most recent disclosure with the SEC. The firm bought 110,460 shares of the biotechnology company’s stock, valued at approximately $1,951,000. Raymond James Financial Inc. owned about 0.23% of uniQure at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Franklin Resources Inc. acquired a new stake in shares of uniQure in the third quarter valued at approximately $7,360,000. Invesco Ltd. raised its position in uniQure by 453.2% in the 4th quarter. Invesco Ltd. now owns 613,601 shares of the biotechnology company’s stock valued at $10,836,000 after purchasing an additional 502,684 shares during the last quarter. Trexquant Investment LP acquired a new stake in uniQure during the 4th quarter worth $2,527,000. Monaco Asset Management SAM acquired a new stake in uniQure during the 4th quarter worth $2,414,000. Finally, JPMorgan Chase & Co. grew its position in uniQure by 14.7% during the 4th quarter. JPMorgan Chase & Co. now owns 453,784 shares of the biotechnology company’s stock worth $8,014,000 after purchasing an additional 58,246 shares during the last quarter. 78.83% of the stock is currently owned by institutional investors and hedge funds.

uniQure Price Performance

Shares of NASDAQ QURE opened at $15.00 on Friday. The company’s fifty day moving average is $12.08 and its two-hundred day moving average is $11.79. The company has a debt-to-equity ratio of 0.92, a quick ratio of 6.51 and a current ratio of 6.51. The firm has a market capitalization of $811.16 million, a P/E ratio of -3.02 and a beta of 0.42. uniQure has a one year low of $3.73 and a one year high of $19.18.

Insider Buying and Selling

In related news, CFO Christian Klemt sold 2,916 shares of uniQure stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $11.32, for a total transaction of $33,009.12. Following the completion of the transaction, the chief financial officer now directly owns 155,168 shares of the company’s stock, valued at approximately $1,756,501.76. The trade was a 1.84 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Matthew C. Kapusta sold 28,341 shares of the company’s stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $10.29, for a total value of $291,628.89. Following the completion of the sale, the chief executive officer now directly owns 651,454 shares in the company, valued at $6,703,461.66. This trade represents a 4.17 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 90,830 shares of company stock valued at $961,401. Corporate insiders own 4.74% of the company’s stock.

Wall Street Analysts Forecast Growth

QURE has been the subject of several recent research reports. Wells Fargo & Company decreased their target price on shares of uniQure from $35.00 to $30.00 and set an “equal weight” rating for the company in a research note on Friday, February 28th. HC Wainwright reaffirmed a “buy” rating and set a $70.00 price objective on shares of uniQure in a research report on Monday, April 21st. Chardan Capital began coverage on uniQure in a report on Tuesday, April 1st. They issued a “buy” rating and a $38.00 target price on the stock. StockNews.com raised uniQure to a “sell” rating in a report on Tuesday, March 11th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $24.00 price objective on shares of uniQure in a research note on Tuesday, January 21st. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, uniQure currently has an average rating of “Moderate Buy” and a consensus target price of $38.80.

uniQure Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.